Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update

BACKGROUND: The COVID-19 pandemic is a concern for people with multiple sclerosis (pwMS), especially those receiving disease-modifying therapies. METHODS: We previously summarized outcomes for 46 pwMS treated with cladribine tablets (CladT) and confirmed or suspected COVID-19, as reported to the Mer...

Descripción completa

Detalles Bibliográficos
Autores principales: Jack, Dominic, Damian, Doris, Nolting, Axel, Galazka, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Topic: Management of MS during the COVID-19 pandemic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250632/
http://dx.doi.org/10.1016/j.msard.2021.102996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250632/
http://dx.doi.org/10.1016/j.msard.2021.102996

Ejemplares similares